Distributional Notes on Three Wolf Spider Species (Araneae: Lycosidae) Recorded for the First Time in Diyala Province, Iraq

  Distributional Notes on Three Wolf Spider Species (Araneae: Lycosidae) Recorded for the First Time in Diyala Province, Iraq Abstract This study presents new distributional data for three wolf spider species (Araneae: Lycosidae) from Diyala Province in eastern Iraq. Specimens were gathered from different districts and habitats between July 2025 and June 2026. The species Arctosa tbilisiensis Mcheidze, 1946, Lycosa piochardi Simon, 1876, and Wadicosa fidelis (O. Pickard-Cambridge, 1872) are recorded for the first time in Diyala, extending their known ranges within Iraq. The paper describes key diagnostic morphological features and includes information about the examined specimens and their local distributions. These findings improve knowledge of the distribution of Iraqi Lycosidae and reveal that Diyala Province, despite its habitat variety, remains insufficiently studied. The records serve as a valuable baseline for future taxonomic, faunistic, and ecological research on spiders i...

Human antibodies neutralizing the alpha-latrotoxin of the European black widow

 


Human antibodies neutralizing the alpha-latrotoxin of the European black widow 

Abstract


Poisoning by widow-spider (genus Latrodectus) bites occurs worldwide. The illness, termed latrodectism, can cause severe and persistent pain and can lead to muscle rigidity, respiratory complications, and cardiac problems. It is a global health challenge especially in developing countries. Equine serum-derived polyclonal anti-sera are commercially available as a medication for patients with latrodectism, but the use of sera imposes potential inherent risks related to its animal origin. The treatment may cause allergic reactions in humans (serum sickness), including anaphylactic shock. Furthermore, equine-derived antivenom is observed to have batch-to-batch variability and poor specificity, as it is always an undefined mix of antibodies. Because latrodectism can be extremely painful but is rarely fatal, the use of antivenom is controversial and only a small fraction of patients is treated. In this work, recombinant human antibodies were selected against alpha-latrotoxin of the European black widow (Latrodectus tredecimguttatus) by phage display from a naïve antibody gene library. Alpha-Latrotoxin (α-LTX) binding scFv were recloned and produced as fully human IgG. A novel alamarBlue assay for venom neutralization was developed and used to select neutralizing IgGs. The human antibodies showed in vitro neutralization efficacy both as single antibodies and antibody combinations. This was also confirmed by electrophysiological measurements of neuronal activity in cell culture. The best neutralizing antibodies showed nanomolar affinities. Antibody MRU44–4-A1 showed outstanding neutralization efficacy and affinity to L. tredecimguttatus α-LTX. Interestingly, only two of the neutralizing antibodies showed cross-neutralization of the venom of the Southern black widow (Latrodectus mactans). This was unexpected, because in the current literature the alpha-latrotoxins are described as highly conserved. The here-engineered antibodies are candidates for future development as potential therapeutics and diagnostic tools, as they for the first time would provide unlimited supply of a chemically completely defined drug of constant quality and efficacy, which is also made without the use of animals.

Ruschig, M., Nerlich, J., Naab, A., Becker, M., Meier, D., Polten, S., Cervantes-Luevano, K., Kuhn, P., Licea Navarro, A. F., Hallermann, S., Dübel, S., Schubert, M., Brown, J., & Hust, M. (2024, April 29). Human antibodies neutralizing the alpha-latrotoxin of the European Black Widow. Frontiers.